Response after treatment with pembrolizumab in a patient with myelophthisis due to melanoma: the role of checkpoint inhibition in the bone

BACKGROUND: Myelophthisis due to melanoma is a rare phenomenon. Treatment strategies for patients with this serious complication of malignancy have not been well documented, and none have previously reported efficacy of immune checkpoint inhibition. Since bone metastases are not measurable lesions p...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosner, Samuel, Sen, Filiz, Postow, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5394614/
https://www.ncbi.nlm.nih.gov/pubmed/28428883
http://dx.doi.org/10.1186/s40425-017-0236-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5394614/
https://www.ncbi.nlm.nih.gov/pubmed/28428883
http://dx.doi.org/10.1186/s40425-017-0236-3

Ejemplares similares